3B BlackBio Dx Ltd
3B BlackBio Dx Ltd (3BBLACKBIO) last reported results for the quarter ended Jun 2026, with sales of ₹33.49 crore and net profit of ₹8.98 crore. The stock last traded at ₹1,640, a market capitalisation of ₹1,408 crore, on a P/E of 25.4. Over the past 52 weeks the stock has ranged between ₹1,084 and ₹1,750. Figures are as of 6 Oct 2026 and are not real time.
3B BlackBio Dx Ltd share price and key metrics
- Current price
- ₹1,640
- Market cap
- ₹1,408 cr
- Stock P/E
- 25.4
- Book value
- ₹378
- ROE
- 19.8%
- ROCE
- 25.5%
- Dividend yield
- 0.31%
- 52w high / low
- 1750/1084
Metrics as of 6 Oct 2026. Not real time.
Track 3B BlackBio Dx Ltd
Cruxal reads every 3B BlackBio Dx Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
3B BlackBio Dx Ltd growth and returns
- 10 Years
- 23%
- 5 Years
- -9%
- 3 Years
- 32%
- TTM
- 54%
- 10 Years
- 68%
- 5 Years
- -12%
- 3 Years
- 31%
- TTM
- 13%
- 10 Years
- 60%
- 5 Years
- 28%
- 3 Years
- 29%
- 1 Year
- 15%
- 10 Years
- 27%
- 5 Years
- 18%
- 3 Years
- 18%
- Last Year
- 20%
3B BlackBio Dx Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹33.49 cr, up 50.7% from ₹22.23 cr a year earlier. Net profit was ₹8.98 cr, down 29.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 29.15 | 25.39 | 22.5 | 22.23 | 33.9 | 50.35 | 35.43 | 33.49 |
| Expenses | 12.98 | 10.32 | 14.58 | 10.4 | 19.17 | 28.63 | 26.94 | 24.97 |
| Operating profit | 16.17 | 15.07 | 7.92 | 11.83 | 14.73 | 21.72 | 8.49 | 8.52 |
| OPM % | 55.47% | 59.35% | 35.20% | 53.22% | 43.45% | 43.14% | 23.96% | 25.44% |
| Other income | 3.44 | 3.01 | 4.94 | 4.32 | 5.51 | 5.59 | 10.15 | 6.14 |
| Interest | 0.03 | 0.02 | 0.04 | 0.01 | 0.04 | 0.09 | 0.1 | 0.1 |
| Depreciation | 0.27 | 0.27 | 0.28 | 0.28 | 0.58 | 0.38 | 3.89 | 1.34 |
| Profit before tax | 19.31 | 17.79 | 12.54 | 15.86 | 19.62 | 26.84 | 14.65 | 13.22 |
| Tax % | 22.99% | 24.17% | 35.89% | 20.30% | 23.34% | 16.39% | 33.11% | 32.07% |
| Net profit | 14.87 | 13.49 | 8.04 | 12.65 | 15.04 | 22.44 | 9.81 | 8.98 |
| EPS (₹) | 17.07 | 15.61 | 9.79 | 14.67 | 17.14 | 25.32 | 11.14 | 11.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
3B BlackBio Dx Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 142 | 153 |
| Operating profit | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 57 | 53 |
| OPM % | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 52% | 40% | 35% |
| Net profit | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 60 | 56 |
| EPS (₹) | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 68.27 | 64.70 |
TTM is the trailing twelve months to the most recent quarter.
3B BlackBio Dx Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
| Reserves | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 | 316 |
| Borrowings | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 3 |
| Other liabilities | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 | 51 |
| Total liabilities | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 378 |
| Fixed assets | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 | 158 |
| Other assets | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 | 193 |
| Total assets | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 378 |
As reported by the company. Total assets equal total liabilities by construction.
3B BlackBio Dx Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 | 52 |
| Cash from investing | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -33 | -24 |
| Cash from financing | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 | -1 |
| Net cash flow | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 7 | 28 |
| Free cash flow | 0 | 1 | 3 | 6 | 96 | 35 | 18 | 26 | 42 | 27 |
| CFO / operating profit | 36% | 52% | 71% | 101% | 90% | 129% | 100% | 115% | 116% | 121% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
3B BlackBio Dx Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% | 26% | 25% |
| Debtor days | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 | 138 | 129 |
| Inventory days | 175 | — | — | — | — | — | 164 | 141 | 124 | 187 |
| Days payable | 186 | — | — | — | — | — | 69 | 66 | 28 | 70 |
| Cash conversion cycle | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 | 245 |
| Working capital days | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 | 143 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
3B BlackBio Dx Ltd shareholding pattern
Promoters held 40.95% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.50% and DIIs 2.15%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 41.28% | 41.28% | 41.28% | 41.28% | 41.28% | 41.27% | 40.94% | 40.95% |
| FIIs | 3.27% | 2.68% | 2.49% | 2.70% | 2.64% | 2.57% | 2.57% | 2.50% |
| DIIs | 1.96% | 1.74% | 1.60% | 1.76% | 1.82% | 1.87% | 1.98% | 2.15% |
| Public | 53.48% | 54.29% | 54.64% | 54.28% | 54.26% | 54.27% | 54.50% | 54.40% |
| No. of shareholders | 9,586 | 10,166 | 10,345 | 10,619 | 10,709 | 10,507 | 10,616 | 11,049 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of 3B BlackBio Dx Ltd
3B BlackBio Dx Ltd corporate filings
- Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- SEBI-regulated re-appointment of senior director at 3B BlackBio Dx Limited signals stable governance; no immediate financial impactCompany Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Limited has disclosed the re-appointment of Mrs. Mithla Dubey, aged 79, as…
Read the full analysis - 3B BlackBio Dx Limited (formerly Kilpest India) votes overwhelmingly in favor of key resolutions at AGM, with 99.99% approval for dividend, reappointment, and remuneration proposalsAGM/EGMhigh impact
Cruxal's analysis: The company, now renamed 3B BlackBio Dx Limited, held its 54th AGM on September 29, 2026…
Read the full analysis - Outcome of AGMAGM/EGMmedium impact
- Closure of Trading WindowInsider Trading / SASTlow impact
- 3B BlackBio Dx Ltd announces special window for re-lodgement of physical share transfer requestsCompany Updatelow impact
Cruxal's analysis: The company has issued a notice regarding a special window for the re-lodgement of…
Read the full analysis - 3B BlackBio Dx Ltd reports outcome of analyst/investor meeting held on September 16, 2026Company Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Ltd has concluded its analyst/investor meeting held on September 16, 2026…
Read the full analysis - 3B BlackBio Dx Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Ltd has issued an intimation regarding an upcoming analyst/investor meet…
Read the full analysis - 3B BlackBio Dx Ltd reports outcome of analyst/investor meeting held on September 11, 2026Company Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Ltd conducted an analyst/investor meeting on September 11, 2026. The…
Read the full analysis - 3B BlackBio Dx Ltd announces routine newspaper publication of financial resultsCompany Updatelow impact
Cruxal's analysis: The company has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - 3B BlackBio Dx Ltd issues routine letter to shareholdersCompany Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Ltd has released a letter to shareholders dated September 7, 2026. The…
Read the full analysis - 3B BlackBio Dx Limited schedules 54th Annual General Meeting for September 29, 2026, and sets record date for dividendAGM/EGMlow impact
Cruxal's analysis: 3B BlackBio Dx Limited has announced that its 54th Annual General Meeting will be held on…
Read the full analysis - 3B BlackBio Dx Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: 3B BlackBio Dx Ltd has filed its Annual Report for the financial year 2025-26 in…
Read the full analysis - 3B BlackBio Dx Limited announces 54th Annual General Meeting for September 29, 2026, with proposal for 50% final dividendAGM/EGMlow impact
Cruxal's analysis: 3B BlackBio Dx Limited has issued a notice for its 54th Annual General Meeting (AGM) to…
Read the full analysis - 3B BlackBio Dx Ltd announces upcoming analyst/investor meetCompany Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Ltd has issued an intimation regarding a scheduled analyst/investor…
Read the full analysis - 3B BlackBio Dx Ltd: Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Ltd has fulfilled its regulatory obligation under Regulation 30 of the…
Read the full analysis - 3B BlackBio Dx Ltd reports outcome of Analyst/Investor meeting held on August 29, 2026Company Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Ltd has concluded its scheduled analyst/investor meeting. The disclosure…
Read the full analysis - 3B BlackBio Dx Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Ltd has issued an intimation regarding an upcoming analyst/investor…
Read the full analysis - 3B BlackBio Dx Limited Reports Q1 FY27 Financial Results with Standalone Net Profit of 8.98 croreCompany Updatelow impact
Cruxal's analysis: 3B BlackBio Dx Limited has released its unaudited standalone and consolidated financial…
Read the full analysis - 3B BlackBio Dx Q1 2026-27 Investor Presentation: Consolidated Revenue Growth Driven by International Expansion and Strategic AcquisitionsCompany Updatehigh impact
Cruxal's analysis: 3B BlackBio Dx Limited reported Q1 2026-27 consolidated revenue of 33.49 crore, up from…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.